Month: May 2025

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor – T cells (CAR-Ts) for immunotherapy with increased function. HCW9206 is a novel class of immunotherapeutic that enables a single molecule to...

Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors. CytoDyn analyzed data from its prior clinical trials of patients with metastatic Triple-Negative Breast Cancer (“mTNBC”) and found that leronlimab treatment correlated with increased expression of an immune cell protein or “checkpoint inhibitor” known as programmed death-ligand 1 (“PD-L1”) on patient’s...

DELAWARE, Ohio, May 13, 2025 (GLOBE NEWSWIRE) — Greif (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, is proud to announce it has been awarded the Supplier Innovation Award by the United States Postal Service (USPS). The Supplier Innovation Award celebrates partners who deliver creative, value-driven solutions that extend beyond contractual obligations. Greif earned this distinction for its part in introducing a custom double-walled corrugated pallet box to replace traditional USPS bulk containers. Manufactured with renewable and recyclable materials, the new lighter-weight box is projected to deliver substantial cost reductions to the USPS—and savings to U.S. taxpayers. “Being recognized by the USPS, one of the nation’s most critical public service organizations, is an incredible honor,”...

MISSISSAUGA, Ontario, May 13, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds an interest in Kruger Products Inc., will release the financial results for KPT and Kruger Products Inc. for the first quarter of 2025 on Wednesday, May 14, 2025 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Conference Call InformationVia telephone: 1-888-699-1199 or 416-945-7677Via internet: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com. Conference Call RebroadcastA rebroadcast of the conference call will be available until midnight, May 21, 2025 by dialing 1-888-660-6345 or 289-819-1450 and entering passcode 89122. The replay of the webcast will remain available on the website until midnight, May 21, 2025. About...

Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC, following the commencement of a Phase 1 clinical trial evaluating Adovate’s lead compound for asthma, ADO-5030. This milestone payment follows Adovate’s exercise of its option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, as previously disclosed. The ongoing Phase 1 study is a...

Range Truck Group joins as key Pacific Northwest partner; third Midwest Ziegler Truck Group location added CINCINNATI, May 13, 2025 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced the expansion of its partnership with Ziegler Truck Group, adding two new dealer locations to its national network. Range Truck Group, located in Fife, Washington, joins the Workhorse dealer family as a key addition in a region leading the charge in electric vehicle adoption. A partner to Ziegler Truck Group, Range specializes in zero-emission commercial vehicles and charging solutions. Its addition enhances Workhorse’s presence in the Pacific Northwest, where demand for reliable, electric last-mile...

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya’s core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated...

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company’s proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a significant milestone in expanding Oragenics’ clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as early as the second quarter of 2025. Once the Company is prepared to commence enrollment, patient enrollment and treatment administration...

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group, and TerraZero is pleased to announce a strategic investment in APX Lending by BIGG Digital Assets and the formation of a partnership between APX Lending and Netcoins.HighlightsBIGG Digital Assets has strategically invested in APX Lending’s latest fundraising round. APX Lending will use the funds for further aggressive growth in Canada and the US. Last month, APX Lending received Exemptive Relief from the Canadian Securities Administrators (CSA) – a first-of-its-kind decision for a crypto-backed lending business in Canada. Netcoins and APX Lending have entered into a partnership...